Home
BlogsMedia
Celiac disease impacts approximately 0.7% (confirmed by biopsy) to 1.4% of the global population (based on positive results for celiac disease antibodies)[1], yet it remains significantly underdiagnosed. This autoimmune condition, triggered by gluten ingestion, can lead to severe intestinal damage,
The global impact of type 1 and type 2 diabetes Diabetes is one of the pressing health challenges of our time. According to the International Diabetes Federation (IDF)[1], 589 million adults worldwide are living with diabetes. This number is projected
The global IVD market portfolio and associated technologies are constantly evolving. AliveDx utilizes innovative technology that provides more automation and multiplex testing to drive lab workflow efficiency. Our MosaiQ® and LumiQ® solutions are designed to help transform autoimmune and allergy
In the world of autoimmune diagnostics, time and accuracy are everything. Traditional serological testing often involves multiple assays, manual steps, and long turnaround times. AliveDx is changing that with the MosaiQ® AiPlex CTDplus, a fully automated multiplex microarray immunoassay designed
In-vitro diagnostics (IVD) is entering a new era, one where artificial intelligence (AI) and multiplexed immunoassays converge to deliver fast, smart and accurate results. At AliveDx, we’re proud to be at the forefront of this transformation with our MosaiQ® and
In–vitro diagnostics (IVD) is undergoing a transformation, driven by automation and a syndromic approach enabled by multiplexing technologies. At AliveDx, we’re proud to lead this evolution with the MosaiQ AiPlex® VAS microarray, a fully automated multiplex immunoassay designed to detect
Autoimmune connective tissue diseases1 (CTD) such as lupus, Sjögren’s syndrome, and systemic sclerosis present a diagnostic challenge due to overlapping symptoms and complex antibody profiles. At AliveDx, we’re committed to the challenge of simplifying that complexity through innovative in-vitro diagnostic